vs

Side-by-side financial comparison of Akebia Therapeutics, Inc. (AKBA) and Southland Holdings, Inc. (SLND). Click either name above to swap in a different company.

Southland Holdings, Inc. is the larger business by last-quarter revenue ($104.0M vs $57.6M, roughly 1.8× Akebia Therapeutics, Inc.). On growth, Akebia Therapeutics, Inc. posted the faster year-over-year revenue change (23.9% vs -61.1%). Akebia Therapeutics, Inc. produced more free cash flow last quarter ($31.1M vs $9.3M). Over the past eight quarters, Akebia Therapeutics, Inc.'s revenue compounded faster (32.9% CAGR vs -39.9%).

Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.

Southland Holdings, Inc. is a leading North American infrastructure construction firm. It offers full-suite services for transportation projects including highways, bridges and airports, water and wastewater system construction, and commercial site development, serving both public sector and private industry clients across regional core markets.

AKBA vs SLND — Head-to-Head

Bigger by revenue
SLND
SLND
1.8× larger
SLND
$104.0M
$57.6M
AKBA
Growing faster (revenue YoY)
AKBA
AKBA
+85.0% gap
AKBA
23.9%
-61.1%
SLND
More free cash flow
AKBA
AKBA
$21.8M more FCF
AKBA
$31.1M
$9.3M
SLND
Faster 2-yr revenue CAGR
AKBA
AKBA
Annualised
AKBA
32.9%
-39.9%
SLND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AKBA
AKBA
SLND
SLND
Revenue
$57.6M
$104.0M
Net Profit
$-216.4M
Gross Margin
78.2%
-186.0%
Operating Margin
-14.8%
-202.4%
Net Margin
-208.2%
Revenue YoY
23.9%
-61.1%
Net Profit YoY
-5108.5%
EPS (diluted)
$-0.05
$-4.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AKBA
AKBA
SLND
SLND
Q4 25
$57.6M
$104.0M
Q3 25
$58.8M
$213.3M
Q2 25
$62.5M
$215.4M
Q1 25
$57.3M
$239.5M
Q4 24
$46.5M
$267.3M
Q3 24
$37.4M
$173.3M
Q2 24
$43.6M
$251.5M
Q1 24
$32.6M
$288.1M
Net Profit
AKBA
AKBA
SLND
SLND
Q4 25
$-216.4M
Q3 25
$540.0K
$-75.3M
Q2 25
$247.0K
$-10.3M
Q1 25
$6.1M
$-4.6M
Q4 24
$-4.2M
Q3 24
$-20.0M
$-54.7M
Q2 24
$-8.6M
$-46.1M
Q1 24
$-18.0M
$-406.0K
Gross Margin
AKBA
AKBA
SLND
SLND
Q4 25
78.2%
-186.0%
Q3 25
84.0%
1.5%
Q2 25
84.1%
6.2%
Q1 25
86.7%
9.0%
Q4 24
56.2%
2.9%
Q3 24
62.2%
-29.5%
Q2 24
60.9%
-15.9%
Q1 24
64.4%
7.1%
Operating Margin
AKBA
AKBA
SLND
SLND
Q4 25
-14.8%
-202.4%
Q3 25
7.6%
-5.3%
Q2 25
22.6%
-0.1%
Q1 25
23.6%
2.1%
Q4 24
-30.8%
-3.0%
Q3 24
-33.4%
-39.6%
Q2 24
-20.0%
-22.1%
Q1 24
-45.8%
2.1%
Net Margin
AKBA
AKBA
SLND
SLND
Q4 25
-208.2%
Q3 25
0.9%
-35.3%
Q2 25
0.4%
-4.8%
Q1 25
10.7%
-1.9%
Q4 24
-1.6%
Q3 24
-53.5%
-31.6%
Q2 24
-19.7%
-18.3%
Q1 24
-55.2%
-0.1%
EPS (diluted)
AKBA
AKBA
SLND
SLND
Q4 25
$-0.05
$-4.01
Q3 25
$0.00
$-1.39
Q2 25
$0.00
$-0.19
Q1 25
$0.03
$-0.08
Q4 24
$-0.10
$-0.08
Q3 24
$-0.10
$-1.14
Q2 24
$-0.04
$-0.96
Q1 24
$-0.09
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AKBA
AKBA
SLND
SLND
Cash + ST InvestmentsLiquidity on hand
$184.8M
$52.7M
Total DebtLower is stronger
$48.3M
$257.7M
Stockholders' EquityBook value
$32.6M
$-140.9M
Total Assets
$376.6M
$989.3M
Debt / EquityLower = less leverage
1.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AKBA
AKBA
SLND
SLND
Q4 25
$184.8M
$52.7M
Q3 25
$166.4M
$40.5M
Q2 25
$137.3M
$46.5M
Q1 25
$113.4M
$65.1M
Q4 24
$51.9M
$72.2M
Q3 24
$34.0M
$91.4M
Q2 24
$39.5M
$52.4M
Q1 24
$42.0M
$31.2M
Total Debt
AKBA
AKBA
SLND
SLND
Q4 25
$48.3M
$257.7M
Q3 25
$47.6M
$267.8M
Q2 25
$47.1M
$278.6M
Q1 25
$46.5M
$288.1M
Q4 24
$38.7M
$300.1M
Q3 24
$38.4M
$318.3M
Q2 24
$38.0M
$307.8M
Q1 24
$30.1M
$302.0M
Stockholders' Equity
AKBA
AKBA
SLND
SLND
Q4 25
$32.6M
$-140.9M
Q3 25
$41.6M
$75.0M
Q2 25
$29.2M
$151.1M
Q1 25
$24.6M
$159.1M
Q4 24
$-49.2M
$163.7M
Q3 24
$-50.4M
$149.1M
Q2 24
$-33.8M
$203.3M
Q1 24
$-27.3M
$249.3M
Total Assets
AKBA
AKBA
SLND
SLND
Q4 25
$376.6M
$989.3M
Q3 25
$364.2M
$1.1B
Q2 25
$345.6M
$1.2B
Q1 25
$310.2M
$1.2B
Q4 24
$220.7M
$1.2B
Q3 24
$207.1M
$1.2B
Q2 24
$220.2M
$1.3B
Q1 24
$225.5M
$1.2B
Debt / Equity
AKBA
AKBA
SLND
SLND
Q4 25
1.48×
Q3 25
1.15×
3.57×
Q2 25
1.61×
1.84×
Q1 25
1.89×
1.81×
Q4 24
1.83×
Q3 24
2.14×
Q2 24
1.51×
Q1 24
1.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AKBA
AKBA
SLND
SLND
Operating Cash FlowLast quarter
$31.1M
$9.7M
Free Cash FlowOCF − Capex
$31.1M
$9.3M
FCF MarginFCF / Revenue
53.9%
8.9%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$67.7M
$12.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AKBA
AKBA
SLND
SLND
Q4 25
$31.1M
$9.7M
Q3 25
$28.1M
$5.9M
Q2 25
$22.3M
$-5.4M
Q1 25
$-13.6M
$6.4M
Q4 24
$-4.5M
$-10.3M
Q3 24
$-6.7M
$-5.3M
Q2 24
$-10.1M
$27.4M
Q1 24
$-19.4M
$-9.9M
Free Cash Flow
AKBA
AKBA
SLND
SLND
Q4 25
$31.1M
$9.3M
Q3 25
$28.0M
$5.3M
Q2 25
$22.2M
$-6.5M
Q1 25
$-13.6M
$4.6M
Q4 24
$-4.5M
$-11.5M
Q3 24
$-6.7M
$-7.3M
Q2 24
$-10.1M
$26.3M
Q1 24
$-13.0M
FCF Margin
AKBA
AKBA
SLND
SLND
Q4 25
53.9%
8.9%
Q3 25
47.7%
2.5%
Q2 25
35.6%
-3.0%
Q1 25
-23.7%
1.9%
Q4 24
-9.6%
-4.3%
Q3 24
-17.9%
-4.2%
Q2 24
-23.1%
10.5%
Q1 24
-4.5%
Capex Intensity
AKBA
AKBA
SLND
SLND
Q4 25
0.1%
0.4%
Q3 25
0.1%
0.3%
Q2 25
0.2%
0.5%
Q1 25
0.0%
0.7%
Q4 24
0.0%
0.5%
Q3 24
0.0%
1.1%
Q2 24
0.1%
0.4%
Q1 24
0.0%
1.1%
Cash Conversion
AKBA
AKBA
SLND
SLND
Q4 25
Q3 25
52.05×
Q2 25
90.47×
Q1 25
-2.22×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AKBA
AKBA

Auryxia$48.1M84%
Vafseo$6.2M11%
License Collaboration And Other Revenue$3.3M6%

SLND
SLND

Civil$58.4M56%
Transportation$45.6M44%

Related Comparisons